Recruiting
Phase 1
Phase 2

Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Sponsor:

ECOG-ACRIN Cancer Research Group

Code:

NCT03504644

Conditions

B Acute Lymphoblastic Leukemia

Lymphoblasts 5 Percent or More of Bone Marrow Nucleated Cells

Recurrent Adult Acute Lymphoblastic Leukemia

Recurrent Childhood Acute Lymphoblastic Leukemia

Refractory Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Laboratory Biomarker Analysis

Venetoclax

Vincristine Liposomal

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information